Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436619 | 0.91 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436297 | 0.90 | KMT2A (0.47) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL13999571 | 0.87 | MEN1 (0.46) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436493 | 0.86 | KMT2A (0.47) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436602 | 0.86 | DRD4 (0.47) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436611 | 0.86 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436410 | 0.85 | KMT2A (0.44) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL13999757 | 0.85 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1L3MBTL1HTT | |
| SCHEMBL3436278 | 0.83 | LMNA (0.55) | ALDH1A1KDM4EMAPTGAAATM | |
| SCHEMBL3436485 | 0.81 | CYP1A2 (0.42) | MEN1KMT2AALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036817-A | C-alkyl carbon glycoside and preparation method thereof | 江西师范大学 | 2026-05-15 | — | — | CN | claimed |
| EP-2586774-A1 | METHOD FOR PREPARATION OF RANOLAZINE | Shanghai Kuoikee Laboratories Co., Ltd (CN) | 2013-05-01 | — | — | EP | claimed |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-04-11 | — | — | US | claimed |
| CN-122036817-A | C-alkyl carbon glycoside and preparation method thereof | 江西师范大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-2586774-A1 | METHOD FOR PREPARATION OF RANOLAZINE | Shanghai Kuoikee Laboratories Co., Ltd (CN) | 2013-05-01 | — | — | EP | disclosed |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-04-11 | — | — | US | disclosed |
| WO-2011160396-A1 | METHOD FOR PREPARATION OF RANOLAZINE | 上海冠杰生物医药科技有限公司 (CN) | 2011-12-29 | — | — | WO | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | MEN1 4851/4885KMT2A 3849/4885ALDH1A1 69/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | MEN1 4701/4885KMT2A 3805/4885ALDH1A1 110/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | MEN1 4701/4885KMT2A 3805/4885ALDH1A1 110/4885 |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | RANBP1, RANBP2, RAN | MEN1 3207/4885KMT2A 1326/4885ALDH1A1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.